-
Views
-
Cite
Cite
E. Angelucci, M. Cesarini, P. Vernia, Nonmelanoma skin cancers in four IBD patients on treatment with immunosuppressive agents, Inflammatory Bowel Diseases, Volume 17, Issue 8, 1 August 2011, Pages 1827–1829, https://doi.org/10.1002/ibd.21609
Close - Share Icon Share
Extract
Nonmelanoma Skin Cancers in Four IBD Patients on Treatment with Immunosuppressive Agents
To the Editor:
We read with interest the recent review in Inflammatory Bowel Diseases by Long et al1 on the risk of nonmelanoma skin cancer (NMSC) in patients with inflammatory bowel disease (IBD).
In a recent cohort study comparing over 52,000 IBD patients with non-IBD controls the incidence of NMSC was higher among IBD patients compared to controls, with an incidence rate ratio 1.64 (95% confidence interval [CI], 1.51–1.78).2 Recent and/or persistent thiopurine use and recent and/or persistent biologic use were also found to be associated with a diagnosis of NMSC.2
As far as risk for NMSC and IBD, two different Northern European studies demonstrated a higher risk for IBD patients compared to the general population. These two epidemiological studies, however, did not evaluate exposure to drugs.3,4
In a cohort of 808 matched-pair Italian Crohn's disease (CD) patients a comparable frequency of newly diagnosed neoplasia was reported in infliximab-treated and untreated patients matched for clinical variables (9 out of 404, 2.22%, versus 7 out of 404, 1.73%; P = 0.40; odds ratio [OR] 1.33, 95% CI 0.46–3.84).5
